Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced promising study results for its core product sacituzumab tirumotecan (sac-TMT) at the 2024 ESMO Congress, highlighting its efficacy and safety in treating various cancers. The biopharmaceutical company reported positive outcomes, including high objective response rates and manageable safety profiles, in patients with cervical, endometrial, and ovarian cancers. The studies underscore sac-TMT’s potential as a monotherapy and in combination with other drugs, supporting ongoing phase 3 trials.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.